A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease

Paul A. Nausieda, Ronald F. Pfeiffer, Michele Tagliati, Kathleen V. Kastenholz, Carole DeRoche, John T. Slevin

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Fingerprint

Dive into the research topics of 'A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease'. Together they form a unique fingerprint.

Medicine & Life Sciences